Ährlund-Richter Andreas, Holzhauser Stefan, Dalianis Tina, Näsman Anders, Mints Michael
Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Department of Clinical Pathology, CCK R8:02, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Cancers (Basel). 2021 Dec 24;14(1):77. doi: 10.3390/cancers14010077.
To identify predictive/targetable markers in human papillomavirus positive (HPV) tonsillar and base of tongue cancer (TSCC/BOTSCC), whole-exome sequencing (WES) of tumours of patients with/without recurrence was performed. Forty primary tumours and adjacent normal tissue were separated by micro-dissection from formalin-fixed paraffin-embedded tissue from patients treated with curative intent 2000-2014 at Karolinska University Hospital. Successful sequencing was obtained in primary tumours of 18 patients without and primaries of 17 with local or distant recurrence, as well as in 10 corresponding recurrences (i.e., five local relapses and five distant metastases) from these 17 patients. One variant-a high-impact deletion in the gene-was observed only in primaries of 5/17 patients that had a recurrence after full treatment but in none of those without recurrence. In addition, 3 variants and 26 mutated genes, including , and , were present in at least 30% of all primary tumours independent of prognosis. To conclude, a deletion was specific and found in ~30% of samples from patients with a local relapse/distant metastasis and could, therefore, potentially be a prospective marker to predict prognosis. Commonly mutated genes, such as , should be further studied in the context of targeted therapy.
为了鉴定人乳头瘤病毒阳性(HPV)扁桃体癌和舌根癌(TSCC/BOTSCC)中的预测性/可靶向性标志物,对有/无复发患者的肿瘤进行了全外显子组测序(WES)。2000年至2014年在卡罗林斯卡大学医院接受根治性治疗的患者,其福尔马林固定石蜡包埋组织经显微切割分离出40个原发性肿瘤和相邻正常组织。在18例无局部或远处复发患者的原发性肿瘤、17例有局部或远处复发患者的原发性肿瘤以及这17例患者的10个相应复发灶(即5个局部复发和5个远处转移)中获得了成功测序。仅在17例中5例接受全疗程治疗后复发患者的原发性肿瘤中观察到1个变异—— 基因中的一个高影响缺失,而无复发患者中未观察到。此外,至少30%的所有原发性肿瘤中存在3个变异和26个突变基因,包括 、 和 ,与预后无关。总之, 缺失具有特异性,在约30%的局部复发/远处转移患者样本中发现,因此可能是预测预后的前瞻性标志物。对于常见的突变基因,如 ,应在靶向治疗背景下进一步研究。